| Identification | Back Directory | [Name]
Cyclo(-Arg-Gly-Asp-D-Phe-Cys) | [CAS]
862772-11-0 | [Synonyms]
RGDfC
C(RGDFC)
Cyclo(-Arg-Gly-Asp-D-Phe-Cys)
CYCLO(ARG-GLY-ASP-D-PHE-CYS);RGDFC
c(RGDfC),cyclo(Arg-Gly-Asp-d-Phe-Cys)
4:PN:WO2020023462 PAGE:42 claimed protein
Cyclo(-Arg-Gly-Asp-D-Phe-Cys)
Acetate salt
Cyclo(-RGDfC), avb3 Integrin Binding Cyclic RGD Peptide
Cyclo(L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-L-cysteinyl)
Cyclo(l-arginylglycyl-l-α-aspartyl-d-phenylalanyl-l-cysteinyl)
Cyclo(-RGDfC), avb3 Integrin Binding Cyclic RGD Peptide, c(RGDfC) | [Molecular Formula]
C24H34N8O7S | [MDL Number]
MFCD16876077 | [MOL File]
862772-11-0.mol | [Molecular Weight]
578.65 |
| Hazard Information | Back Directory | [Uses]
Cyclo(L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-L-cysteinyl) is a peptide molecule which can be conjugated with hyperbranched amphiphilic block copolymer for cancer-targeted drug delivery and non-invasive positron emission tomography (PET) imaging in tumor-bearing mice. | [in vivo]
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5 mM, 24 h)-treated mESCs in the presence/absence of Leukemia inhibitory factor (LIF) (injected in both thighs) generated teratomas in severe combined immunodeficiency (SCID) mice, which indicates that the process of mESC tumor formation in vivo is dependent on integrin interaction[1].
| [IC 50]
αvβ3 |
|
|